Fetuin-A levels and Insulin Resistance in Obese and Non-Obese Iraqi Children

Main Article Content

Raghda Shams Akram
Maryam Qusay Isaa
Ammar Abdulkhalek Mohammed


Fetuin A, Insulin Resistance , Lipid Profile, Obesity


The study's objective was to assess fetuin-A serum levels in persons with and without obesity and their potential relationships with other laboratory and clinical factors. In this case-control study, 60 obese Iraqi children (30 boys and 30 girls) participated, with 30 non-obese Iraqi children serving as the control group (15 boy, 15 girl). The subject's age ranges from nine to sixteen. Obese subjects had higher serum fetuin-A levels than lean subjects. Significant correlations were seen between greater serum fetuin-A levels and metabolic syndrome patients. In obese children with IR, there are positive correlations between Fetuin-A and SBP, DBP, weight, BMI, FBG, HOMA-IR, TG, and LDL-C, but a negative significant association with HDL-C. It can conclude that obese kids have higher fetuin-A concentrations than normal kids. These results support the idea that fetuin-A and Met S have a functionally relevant relationship in obesity and play a significant role in the pathophysiology of metabolic disease in obese children. Insulin resistance and other characteristics of the Metabolic syndrome, Significant correlations exist between fetuin-A and other factors, such as elevated BMI, elevated blood pressure, and lowered HDL-C.

Abstract 127 | pdf Downloads 131


1. Demiral, M. (2021) ‘A novel diagnostic tool in determining insulin resistance in obese children: Triglyceride/HDL ratio’, J Surg Med, 5(11), pp. 1144–1147.
2. Organization, W. H. (2012) ‘Fact Sheet No. 311 (May 2012)’.
3. Rodríguez, A. et al. (2007) ‘Visceral and subcutaneous adiposity: are both potentialtherapeutic targets for tackling the metabolic syndrome?’, Current pharmaceutical design, 13(21), pp. 2169–2175.
4. Scorletti, E., Calder, P. C. and Byrne, C. D. (2011) ‘Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments’, Endocrine, 40, pp. 332–343.
5. Weston, S. R. et al. (2005) ‘Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease’, Hepatology, 41(2), pp. 372–379.
6. Tagi, V. M., Giannini, C. and Chiarelli, F. (2019) ‘Insulin resistance in children’, Frontiers in endocrinology, 10, p. 342.
7. Lebovitz, H. E. (2001) ‘Insulin resistance: definition and consequences’, Experimental and clinical endocrinology & diabetes, 109(Suppl 2), pp. S135–S148.
8. Caprio, S. (2002) ‘Insulin resistance in childhood obesity.’, Journal of pediatric endocrinology & metabolism: JPEM, 15, pp. 487–492.
9. Stefan, N. et al. (2006) ‘α2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans’, Diabetes care, 29(4), pp. 853–857.
10. Trepanowski, J. F., Mey, J. and Varady, K. A. (2015) ‘Fetuin-A: a novel link between obesity and related complications’, International journal of obesity, 39(5), pp. 734–741.
11. Pérez-Sotelo, D. et al. (2017) ‘Visceral and subcutaneous adipose tissue express and secrete functional alpha2hsglycoprotein (fetuin a) especially in obesity’, Endocrine, 55, pp. 435–446.
12. Ou, H.-Y. et al. (2012) ‘Increased fetuin-A concentrations in impaired glucose tolerance with or without nonalcoholic fatty liver disease, but not impaired fasting glucose’, The Journal of Clinical Endocrinology & Metabolism, 97(12), pp. 4717–4723.
13. Khadir, A. et al. (2018) ‘Fetuin-A levels are increased in the adipose tissue of diabetic obese humans but not in circulation’, Lipids in health and disease, 17, pp. 1–13.
14. Coen, P. M., Carnero, E. A. and Goodpaster, B. H. (2018) ‘Exercise and bariatric surgery: an effective therapeutic strategy’, Exercise and sport sciences reviews, 46(4), p. 262.
15. Subcommittee, G. and Organization, W. H. (1999) ‘International Society of Hypertension guidelines for the management of hypertension’, J Hypertens, 17(2), pp. 151–183.
16. Barlow, S. E. (no date) ‘Expert, Committee.(2007). Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent
overweight and obesity: Summary report’, Pediatrics, 120(4), pp. 164–192.
17. Trinder, P. (1969) ‘Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor’, Annals of clinical Biochemistry, 6(1), pp. 24–27.
18. Fossati, P. and Prencipe, L. (1982) ‘Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide.’, Clinical chemistry, 28(10), pp. 2077–2080.
19. Burstein, M., Scholnick, H. R. and Morfin, R. (1970) ‘Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions’, Journal of lipid research, 11(6), pp. 583–595.
20. Judzewitsch, R. G. et al. (1982) ‘Chronic chlorpropamide therapy of noninsulin-dependent diabetes augments basal and stimulated insulin secretion by increasing islet sensitivity to glucose’, The Journal of Clinical Endocrinology & Metabolism, 55(2), pp. 321–328.
21. Tara, M. W., Jonathan, C. L. and David, R. M. (2004) ‘Use and abuse of HOMA modeling’, Diabetes care, 27(6), pp. 1487–1495.
22. Ix, J. H., Shlipak, M. G., et al. (2006) ‘Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study’, Circulation, 113(14), pp. 1760–1767.
23. Bourebaba, L. and Marycz, K. (2019) ‘Pathophysiological implication of fetuin-A glycoprotein in the development of metabolic disorders: a concise review’, Journal of Clinical Medicine, 8(12), p. 2033.
24. Ix, J. H., Chertow, G. M., et al. (2006) ‘Fetuin-A and kidney function in persons with coronary artery disease—data from the Heart and Soul Study’, Nephrology Dialysis Transplantation, 21(8), pp. 2144–2151.
25. Ismail, N. A. et al. (2012) ‘Fetuin-A levels in obesity: differences in relation to metabolic syndrome and correlation with clinical and laboratory variables’, Archives of Medical Science, 8(5), pp. 826–833.
26. Reinehr, T. and Roth, C. L. (2008) ‘Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss’, The Journal of Clinical Endocrinology & Metabolism, 93(11), pp. 4479–4485.
27. Xu, Y. et al. (2011) ‘Serum fetuin-A is correlated with metabolic syndrome in middle-aged and elderly Chinese’, Atherosclerosis, 216(1), pp. 180–186.
28. Kalabay, L. et al. (1998) ‘Human recombinant alpha2-HS glycoprotein is produced in insect cells as a full length inhibitor of the insulinreceptor tyrosine kinase’, Hormone and metabolic research, 30(01), pp. 1–6.
29. Vionnet, N. et al. (2000) ‘Genomewide search for type 2 diabetes–susceptibility genes in French Whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2–diabetes locus on chromosome 1q21–q24’, The American Journal of Human Genetics, 67(6), pp. 1470–1480.
30. Hennige, A. M. et al. (2008) ‘Fetuin-A induces cytokine expression and suppresses adiponectin production’, PloS one, 3(3), p. e1765.
31. Kadowaki, T. et al. (2006) ‘Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome’, The Journal of clinical investigation, 116(7), pp. 1784–1792.
32. Dahlman, I. et al. (2004) ‘α 2-Heremans–Schmid glycoprotein gene polymorphisms are associated with adipocyte insulin action’, Diabetologia, 47, pp. 1974–1979.